WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018005676) FORMULATIONS OF BRINCIDOFOVIR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/005676 International Application No.: PCT/US2017/039804
Publication Date: 04.01.2018 International Filing Date: 28.06.2017
IPC:
A61K 9/08 (2006.01) ,A61K 9/19 (2006.01) ,A61K 47/18 (2017.01) ,A61K 47/26 (2006.01) ,A61K 31/685 (2006.01)
Applicants: CHIMERIX, INC.[US/US]; 2505 Meridian Parkway Suite 340 Durham, North Carolina 27713, US
Inventors: KABIR, Mohammed Anowrul; US
NADERER, Odin Johann; US
GROSSI, Irma Marisa; US
Agent: ERLACHER, Heidi A.; US
ELRIFI, Ivor R.; US
WESPE, Daniel A.; US
Priority Data:
62/355,84428.06.2016US
62/394,66514.09.2016US
62/446,21313.01.2017US
62/465,05328.02.2017US
62/507,39717.05.2017US
62/512,82531.05.2017US
Title (EN) FORMULATIONS OF BRINCIDOFOVIR
(FR) FORMULATIONS DE BRINCIDOFOVIR
Abstract: front page image
(EN) Disclosed are formulations comprising brincidofovir. The formulations can be intravenous formulations. The formulations can be used in cases where a subject experiences gastrointestinal issues in response to oral administration of brincidofovir. The formulations can also be used in cases where oral administration of drug is not possible due to underlying conditions or concern around inadequate oral absorption.
(FR) L'invention concerne des formulations comprenant du brincidofovir. Les formulations peuvent être des formulations intraveineuses. Les formulations peuvent être utilisées dans les cas où un sujet a des problèmes gastro-intestinaux en réponse à l'administration orale de brincidofovir. Les formulations peuvent également être utilisées dans les cas où l'administration orale de médicament n'est pas possible en raison de troubles sous-jacents ou d'un problème d'absorption orale inadéquate.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)